ERBB2 and cancer: Similarly, cancer resistance to Her-2 inhibitors was successfully overcome when they were used in combination with FGFR inhibitors, thereby providing a rationale for dual inhibition of these pathways to overcome the resistance to Her-2 inhibitors [171].